Leverinsufficiens Pegasys’ s farmakokinetik var ens hos raske forsøgspersoner og hos patienter med hepatitis B eller C.
Hepatic impairment The pharmacokinetics of Pegasys were similar between healthy subjects and patients with hepatitis B or C.